phenyl-(2-phenyl-imidazo[1,2-a]pyrazin-3-yl)-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: phenyl-(2-phenyl-imidazo[1,2-a]pyrazin-3-yl)-amine
• 英文别名: N,2-diphenylimidazo[1,2-a]pyrazin-3-amine
• 化学式: C₁₈H₁₄N₄
• 分子量: 286.336
• InChiKey: YEDCGDBCGNIOGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Oncalis AG

  公开号：EP1765351B1

  公开（公告）日：2009-03-04
• ANGIOGENESIS INHIBITORS
  申请人：Oncalis AG

  公开号：EP1901748B1

  公开（公告）日：2010-09-08
• Protein kinase inhibitors
  申请人：Berset Catherine

  公开号：US20070149535A1

  公开（公告）日：2007-06-28

  The present invention relates to angiogenesis inhibitors, in particular receptor tyrosine kinase inhibitors, and their use for the treatment of hyperproliferative diseases, angiogenesis and disorders depending on angiogenesis such as tumour forming cancers. It also relates to a method of inhibiting angiogenesis or treating a vascular anomaly in a mammal comprising administering to the mammal an amount of an Eph receptor inhibitor which is effective for inhibiting angiogenesis or for treating the vascular anomaly in the mammal. Further, the present invention relates to the use of compounds for the treatment of angiogenesis related disorders involving a protein kinase, preferably a tyrosine kinase, and to some specific forms of said compounds as a medicament. Compounds useful in the practice of the invention have the general formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification.